GlobeNewswire·Nov 10, 2025, 4:01 PM ET

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

Enrollment has begun in the second dose-escalation cohort for the NKX019 clinical program.
Deep B-cell depletion was observed in all patients receiving NKX019 with a lymphodepletion regimen of fludarabine & cyclophosphamide, compared to partial depletion with cyclophosphamide alone.
Enrollment for Ntrust-1 & Ntrust-2 trials was streamlined under a combined independent Data Safety Monitoring Board to guide dose escalation decisions.
Patient-by-patient stagger protocols were eliminated to allow simultaneous dosing of multiple participants within each dose cohort.
Initial data for NKX019 in multiple autoimmune indications is expected to be presented at a medical conference in 2026.
Cash, cash equivalents, & investments totaled $316.5 million as of September 30, 2025, sufficient to fund operations into 2029.
Third quarter 2025 research & development expenses were $20.2 million, while general & administrative expenses were $7.1 million.
Net loss for the third quarter of 2025 was $21.7 million, or $0.29 per share.
Ntrust-1 & Ntrust-2 trials are enrolling patients across lupus nephritis, primary membranous nephropathy, systemic sclerosis, idiopathic inflammatory myopathy, & ANCA-associated vasculitis.
Investigator-sponsored trials for generalized myasthenia gravis & systemic lupus erythematosus are also ongoing to evaluate safety & clinical outcomes.